Changeflow GovPing Government General Green Lumber Holdings Recalls Natural Fuel For ...
Urgent Enforcement Amended Final

Green Lumber Holdings Recalls Natural Fuel For Men Capsules

Favicon for changeflow.com FDA Drug Recalls (Class I)
Filed
Detected
Email

Summary

Green Lumber Holdings, LLC initiated a voluntary Class I recall of its Natural Fuel For Men capsules after FDA analysis found the product contained tadalafil, an unapproved drug ingredient. The recall affects one lot (LOT308EXP03/28) distributed nationwide in 2, 4, 10, and 30-count blister packs. The firm initiated the recall on August 28, 2025; FDA classified it as Class I on February 10, 2026.

Published by FDA on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

Green Lumber Holdings initiated a voluntary Class I recall of Natural Fuel For Men capsules after FDA analysis determined the product contained tadalafil, an unapproved drug ingredient marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). The affected lot is LOT308EXP03/28, distributed nationwide in various blister pack sizes.\n\nDrug manufacturers and distributors should verify whether they hold or have distributed this product and take appropriate quarantine and removal actions. Consumers who have purchased this product should discontinue use and contact the firm. Class I recalls are the most serious FDA designation, indicating reasonable probability that use of the product will cause adverse health consequences or death.

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Green Lumber Holdings, LLC

Drug Recalls (Class I)

← All Drug Recalls (Class I) Class I D-0304-2026 · 20260211 · Ongoing · Voluntary: Firm initiated

Product

Green Lumber Natural Fuel For Men capsule, packaged in 2, 4, 10, and 30-count blister packs. GreenLumber.com, 2618 San Miguel Drive, Suite #296, Newport Beach, CA 92660

Reason for Recall

Marketed without an Approved NDA/ANDA: FDA analysis found this product to contain tadalafil

Affected Lot Numbers / Codes

LOT308EXP03/28

Quantity

N/A

Firm Notification Method

Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Distribution

Nationwide

Initiated

20250828

FDA Classified

20260210

Sources: openFDA · Raw JSON

Get daily alerts for FDA Drug Recalls (Class I)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Filed
February 10th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
D-0304-2026

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug recall response
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Public Health Consumer Protection

Get alerts for this source

We'll email you when FDA Drug Recalls (Class I) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!